Aptevo Therapeutics Inc.

What they do

Aptevo discovers and develops novel immunotherapy candidates designed to modulate the immune system against cancer. Its two clinical candidates are mipletamig, a CD123xCD3 T cell engager in the Phase 1b/2 RAINIER trial in frontline acute myelogenous leukemia (AML) combined with venetoclax plus azacitidine, and ALG.APV-527, a 4-1BB/5T4 candidate for solid tumors developed with Alligator Bioscience AB. Six preclinical candidates (APVO603, APVO711, APVO442, APVO455, APVO451 and APVO452) were generated from the wholly owned ADAPTIR and ADAPTIR-FLEX platforms.

Revenue drivers

• Product revenue — Aptevo has no approved products; the last reported annual revenue was $3.1 million in 2022, and no meaningful product revenue appears in the provided data for 2023 through 2025.
• Mipletamig (CD123xCD3) — The lead clinical asset and central value driver, in the Phase 1b/2 RAINIER trial in frontline AML; it is not yet commercialized and generates no revenue.
• ALG.APV-527 (4-1BB/5T4) — Solid tumor candidate developed in partnership with Alligator Bioscience AB; a dose escalation trial of nineteen patients across five cohorts showed 58% of patients achieved best response of stable disease.
• Platform licensing and collaborations — The company states its wholly owned ADAPTIR and ADAPTIR-FLEX platforms support pipeline growth; the 10-K notes dependence on establishing and maintaining collaborations, but no collaboration revenue figure is provided in the excerpts.

Recent performance

The company reported a net loss of $26.0 million for the year ended December 31, 2025, compared with a $24.1 million net loss in 2024, and held $21.6 million in cash and cash equivalents as of December 31, 2025. Operating cash flow was negative $25.6 million in 2025 versus negative $23.8 million in 2024. At June 30, 2026, total assets were $14.5 million, total liabilities $8.5 million, shareholder equity $6.0 million and cash and equivalents $9.8 million. In the second quarter of 2026, Aptevo reported RAINIER data across 31 evaluable unfit frontline AML patients showing an 87% clinical benefit rate and an 81% remission rate, with 55% of CR/CRi patients reaching MRD-negative status, 36% of remissions carrying the TP53 mutation, and six patients bridged to allogeneic stem cell transplant.

Strategy

Management's priority is advancing mipletamig through the RAINIER Phase 1b/2 trial, completing dose optimization by year end and selecting a recommended Phase 2 dose ahead of a Phase 2 regulatory interaction in the first quarter of 2027. Aptevo continues clinical work on ALG.APV-527 in 5T4-expressing solid tumors with Alligator Bioscience. It has expanded its CD3-engaging portfolio to five molecules, including first trispecific assets, and secured non-dilutive grant funding to advance APVO451. The company also entered a 50/50 collaboration with Niowave to pursue radiopharmaceutical therapeutics and isotope supply, and in 2026 established a $60 million equity line facility.

Risks

• Going concern — Management and the board concluded substantial doubt exists about Aptevo's ability to continue as a going concern.
• Capital needs — The company has a history of losses and states it will require additional capital, which it may be unable to raise when needed or on acceptable terms.
• Nasdaq listing — Aptevo's common stock may be at risk for delisting from the Nasdaq Capital Market if it does not maintain continued listing requirements.
• Clinical and regulatory execution — Success depends on commencing, enrolling and completing clinical trials and obtaining regulatory approval for product candidates that currently generate no revenue.

Outlook

Management expects to complete the Phase 1b RAINIER portion and select the recommended Phase 2 dose by the end of 2026, followed by a Phase 2 regulatory interaction in the first quarter of 2027. It cites non-dilutive funding for APVO451 and the Niowave radiopharmaceutical collaboration as new development opportunities. The company states that the $60 million equity line facility, if fully utilized together with current resources, is expected to support operations into 2029.